Tessier-Lavigne Marc has filed 8 insider transactions across 2 companies since January 2023.
Most recent transaction: a grant/award of 6037 shares of Denali Therapeutics Inc. ($DNLI) on June 03, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 3, 2025 | Denali Therapeutics Inc. | $DNLI | Tessier-Lavigne Marc | Director | A | Common Stock | 6037 | $0.00 | 2,123,445.0000 | 164,473,772 | 0.29% | 0.00% |
| June 3, 2025 | Denali Therapeutics Inc. | $DNLI | Tessier-Lavigne Marc | Director | A | Stock Option (right to buy) | 18111 | $0.00 | 18,111.0000 | 164,473,772 | 9999.99% | 0.01% |
| May 31, 2024 | Denali Therapeutics Inc. | $DNLI | Tessier-Lavigne Marc | Director | A | Common Stock | 5967 | $0.00 | 2,117,408.0000 | 137,370,897 | 0.28% | 0.00% |
| May 31, 2024 | Denali Therapeutics Inc. | $DNLI | Tessier-Lavigne Marc | Director | A | Stock Option (right to buy) | 17901 | $0.00 | 17,901.0000 | 137,370,897 | 9999.99% | 0.01% |
| Jan. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Tessier-Lavigne Marc | Director | A | Common Stock | 165 | $0.00 | 2,434.0000 | 130,400,000 | 7.27% | 0.00% |
| Jan. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Tessier-Lavigne Marc | Director | A | Non-Qualified Stock Option (right to buy) | 1929 | $0.00 | 1,929.0000 | 130,400,000 | 9999.99% | 0.00% |
| Jan. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Tessier-Lavigne Marc | Director | A | Common Stock | 165 | $0.00 | 2,434.0000 | 130,400,000 | 7.27% | 0.00% |
| Jan. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Tessier-Lavigne Marc | Director | A | Non-Qualified Stock Option (right to buy) | 1929 | $0.00 | 1,929.0000 | 130,400,000 | 9999.99% | 0.00% |